Tuesday, September 15, 2026

Sanofi and Cheplapharm plan mature medicines partnership

Sanofi and Cheplapharm intend to broaden their existing relationship through a strategic partnership focused on mature medicines. Under the planned agreement, Cheplapharm would take over 20 established medicines from Sanofi and three manufacturing sites. In return, Sanofi would receive a 26.4 percent equity stake in Cheplapharm.

The companies said the planned structure builds on a collaboration that began in 2014. Sanofi is continuing to concentrate resources on innovation, while Cheplapharm, a Germany-based European specialist in established originator medicines, would manage the products through the next stage of their lifecycle.

Three manufacturing sites included

The proposed transfer covers sites in Csanyikvölgy, Hungary, Jurong, Singapore, and Ploërmel, France. According to the companies, the locations employ around 400, 100 and 65 people respectively. Existing employment arrangements and collective agreements are expected to remain in place.

Sanofi and Cheplapharm said they plan to coordinate closely during the transition. The stated aim is to maintain product supply while meeting applicable manufacturing quality standards.

Commercial transfer targeted for 2027

The commercial handover of the medicine portfolio is expected to start in the first quarter of 2027. The transfer of the manufacturing sites is planned to follow, subject to employee information and consultation processes, regulatory approvals and customary closing conditions.

The companies currently expect the transaction to be fully completed by the third quarter of 2027. Sanofi said the medicines covered include Lovenox/Clexane, or enoxaparin, excluding the United States.

Portfolio focus and growth strategy

Sanofi does not expect the proposed transaction to affect its 2026 financial guidance. Additional financial details are expected at a later stage.

For Cheplapharm, the agreement would add scale to its business in established medicines. The company says it has invested more than 6.2 billion euros since its inception, acquired nearly 100 products since 2015 and holds 3,440 marketing authorizations across 160 countries.